Overview
ZL-1102 is a human VH antibody fragment being developed for the topical treatment of mild/moderate chronic plaque psoriasis. In 2018, Zai obtained an exclusive, worldwide license to develop and commercialize ZL-1102 from Crescendo Biologics Ltd. IL-17 inhibition in local psoriatic lesions is considered the key therapeutic mechanism for IL-17 antibodies. IL-17 inhibitors have consistently demonstrated better lesion clearance relative to older therapeutics. Despite their unprecedented efficacy, systemic therapy with IL-17 antibodies can result in safety issues due to immunosuppression. In contrast, ZL-1102 is designed to be administered topically, thus avoiding significant systemic exposure. As a result of these distinguishing properties, ZL-1102 could provide a new treatment modality for psoriasis patients, especially those with milder disease, for whom currently available IL-17 inhibitors are not indicated.
Mechanism of Action
ZL-1102 is a human VH antibody fragment targeting IL-17 with high affinity and avidity.